$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2011 Form 10-K Financial Statement

#000110465912021373 Filed on March 27, 2012

Income Statement

Concept	2011	2010 Q4	2010
Revenue	$15.69M	$2.200M	$14.56M
YoY Change	7.74%	-48.84%	-2.96%
Cost Of Revenue	$16.74M	$2.100M	$12.28M
YoY Change	36.36%	-40.0%	-0.2%
Gross Profit	-$1.050M	$100.0K	$2.286M
YoY Change	-145.93%	-87.5%	-15.49%
Gross Profit Margin	-6.69%	4.55%	15.7%
Selling, General & Admin	$20.16M	$2.400M	$6.367M
YoY Change	216.62%	118.18%	26.83%
% of Gross Profit		2400.0%	278.52%
Research & Development	$14.87M	$3.700M	$18.63M
YoY Change	-20.16%	-50.67%	-28.99%
% of Gross Profit		3700.0%	814.87%
Depreciation & Amortization	$4.314M	$1.000M	$4.071M
YoY Change	5.97%	-1.96%	-1.81%
% of Gross Profit		1000.0%	178.08%
Operating Expenses	$54.79M	$6.100M	$37.27M
YoY Change	47.0%	-29.07%	-14.43%
Operating Profit	-$39.10M	-$6.000M	-$22.71M
YoY Change	72.18%	-23.08%	-20.45%
Interest Expense	$4.780M	-$1.300M	$3.959M
YoY Change	20.74%	85.71%	129.77%
% of Operating Profit
Other Income/Expense, Net	-$4.227M	$500.0K	-$4.440M
YoY Change	-4.8%	-200.0%	40.55%
Pretax Income	-$43.33M	-$7.000M	-$27.10M
YoY Change	59.88%	-22.22%	-14.51%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$43.33M	-$7.000M	-$27.15M
YoY Change	59.59%	-22.22%	-14.38%
Net Earnings / Revenue	-276.17%	-318.18%	-186.44%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.517M	-$407.0K	-$1.576M
COMMON SHARES
Basic Shares Outstanding	16.44M shares		574.0K shares
Diluted Shares Outstanding	16.44M shares		574.1K shares

Balance Sheet

Concept	2011	2010 Q4	2010
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.20M	$26.10M	$26.10M
YoY Change	191.95%		267.61%
Cash & Equivalents	$46.20M	$26.13M	$26.10M
Short-Term Investments	$30.00M	$0.00	$0.00
Other Short-Term Assets	$3.100M	$2.100M	$2.100M
YoY Change	47.62%		-8.7%
Inventory	$1.200M	$1.605M	$1.600M
Prepaid Expenses
Receivables	$2.100M	$1.191M	$1.200M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$82.60M	$31.06M	$31.10M
YoY Change	165.59%		148.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.10M	$23.95M	$24.00M
YoY Change	4.58%		22.45%
Goodwill
YoY Change
Intangibles		$8.912M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$2.645M	$2.600M
YoY Change	-80.77%		271.43%
Total Long-Term Assets	$30.90M	$35.51M	$35.50M
YoY Change	-12.96%		12.7%
TOTAL ASSETS
Total Short-Term Assets	$82.60M	$31.06M	$31.10M
Total Long-Term Assets	$30.90M	$35.51M	$35.50M
Total Assets	$113.5M	$66.56M	$66.60M
YoY Change	70.42%		51.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.400M	$4.315M	$4.300M
YoY Change	-20.93%		-38.57%
Accrued Expenses	$2.800M	$4.983M	$600.0K
YoY Change	366.67%		20.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.300M	$3.182M	$5.900M
YoY Change	40.68%		78.79%
Total Short-Term Liabilities	$31.90M	$16.32M	$16.30M
YoY Change	95.71%		13.19%
LONG-TERM LIABILITIES
Long-Term Debt	$20.10M	$21.87M	$74.70M
YoY Change	-73.09%		189.53%
Other Long-Term Liabilities	$13.20M	$3.783M	$24.00M
YoY Change	-45.0%		-10.11%
Total Long-Term Liabilities	$33.30M	$25.65M	$98.70M
YoY Change	-66.26%		88.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.90M	$16.32M	$16.30M
Total Long-Term Liabilities	$33.30M	$25.65M	$98.70M
Total Liabilities	$65.20M	$114.9M	$114.9M
YoY Change	-43.26%		71.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$136.9M
YoY Change
Common Stock		$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.000K
YoY Change
Treasury Stock Shares		1.065K shares
Shareholders Equity	$48.30M	-$48.38M	-$48.40M
YoY Change
Total Liabilities & Shareholders Equity	$113.5M	$66.56M	$66.60M
YoY Change	70.42%		51.36%

Cashflow Statement

Concept	2011	2010 Q4	2010
OPERATING ACTIVITIES
Net Income	-$43.33M	-$7.000M	-$27.15M
YoY Change	59.59%	-22.22%	-14.38%
Depreciation, Depletion And Amortization	$4.314M	$1.000M	$4.071M
YoY Change	5.97%	-1.96%	-1.81%
Cash From Operating Activities	-$31.00M	-$5.840M	-$24.88M
YoY Change	24.6%	-795.24%	19.39%
INVESTING ACTIVITIES
Capital Expenditures	$6.167M	-$2.950M	$6.770M
YoY Change	-8.91%	637.5%	22.89%
Acquisitions
YoY Change
Other Investing Activities	-$29.96M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$36.12M	-$2.950M	-$6.770M
YoY Change	433.53%	637.5%	22.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$49.01M		$2.000K
YoY Change	2450200.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	87.16M	21.07M	50.71M
YoY Change	71.88%	844.84%	141.02%
NET CHANGE
Cash From Operating Activities	-31.00M	-5.840M	-24.88M
Cash From Investing Activities	-36.12M	-2.950M	-6.770M
Cash From Financing Activities	87.16M	21.07M	50.71M
Net Change In Cash	20.04M	12.28M	19.06M
YoY Change	5.14%	359.93%	-458.95%
FREE CASH FLOW
Cash From Operating Activities	-$31.00M	-$5.840M	-$24.88M
Capital Expenditures	$6.167M	-$2.950M	$6.770M
Free Cash Flow	-$37.17M	-$2.890M	-$31.65M
YoY Change	17.43%	-333.06%	20.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113490000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	48269000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180239000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	228470000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	25000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	65221000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2778000	USD
CY2011Q4	pcrx	Contingent Purchase Liability ContingentPurchaseLiability	2042000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8416000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	1537000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18537000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31911000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13054000	USD
CY2011Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1219000	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5259000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25103000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	82649000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	1245000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2113000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	29985000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1299000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46168000	USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66562000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7159000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3440000	USD
CY2011Q4	us-gaap	Assets Assets	113490000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	479000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-48383000	USD
CY2010Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136911000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	114945000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3783000	USD
CY2010Q4	pcrx	Contingent Purchase Liability ContingentPurchaseLiability	2042000	USD
CY2010Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18138000	USD
CY2010Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	2996000	USD
CY2010Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21869000	USD
CY2010Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	49795000	USD
CY2010Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3182000	USD
CY2010Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2267000	USD
CY2010Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	1575000	USD
CY2010Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4983000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4315000	USD
CY2010Q4	us-gaap	Assets Assets	66562000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2645000	USD
CY2010Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8912000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23950000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	31055000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	812000	USD
CY2010Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1191000	USD
CY2010Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1314000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26133000	USD
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	575095	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	6322640	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	88000000	shares
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	6322640	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2011	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	5074000	USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011	us-gaap	Interest Expense InterestExpense	4780000	USD
CY2009	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-55.32
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	-28548000	USD
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4440000	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000	USD
CY2011	us-gaap	Royalty Expense RoyaltyExpense	-227000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	255000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-39101000	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3019000	USD
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20159000	USD
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	16739000	USD
CY2011	us-gaap	Revenues Revenues	15689000	USD
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	574072	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	574072	shares
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-47.29
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	487000	USD
CY2010	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-184000	USD
CY2010	us-gaap	Interest Expense InterestExpense	3959000	USD
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	146000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-22709000	USD
CY2010	us-gaap	Operating Expenses OperatingExpenses	37271000	USD
CY2010	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6367000	USD
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18628000	USD
CY2010	us-gaap	Cost Of Revenue CostOfRevenue	12276000	USD
CY2010	us-gaap	Revenues Revenues	14562000	USD
CY2010	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	3217000	USD
CY2009	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	573118	shares
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-31707000	USD
CY2009	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3159000	USD
CY2009	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	367000	USD
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16437464	shares
CY2009	us-gaap	Royalty Expense RoyaltyExpense	1880000	USD
CY2009	us-gaap	Interest Expense InterestExpense	1723000	USD
CY2009	us-gaap	Investment Income Interest InvestmentIncomeInterest	77000	USD
CY2009	us-gaap	Operating Expenses OperatingExpenses	43554000	USD
CY2009	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5020000	USD
CY2009	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26233000	USD
CY2009	us-gaap	Cost Of Revenue CostOfRevenue	12301000	USD
CY2009	us-gaap	Revenues Revenues	15006000	USD
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16437464	shares
CY2009	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	4638000	USD
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.64
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-43328000	USD
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4227000	USD
CY2011	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2011	dei	Document Type DocumentType	10-K
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2011	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2011	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2011	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2011Q2	dei	Entity Public Float EntityPublicFloat	65885400	USD
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25410791	shares
CY2011	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2011	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	29970000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-36123000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6769000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5509000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	136000	USD
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2009	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2011	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	38016000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	49006000	USD
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2000	USD
CY2010	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7500000	USD
CY2009	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10625000	USD
CY2010	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	56250000	USD
CY2009	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	314000	USD
CY2011	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1644000	USD
CY2010	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	146000	USD
CY2009	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	600000	USD
CY2011	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-273000	USD
CY2010	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11000	USD
CY2009	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1707000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	2493000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	23000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	524000	USD
CY2011	pcrx	Change In Royalty Interest Obligation ChangeInRoyaltyInterestObligation	1815000	USD
CY2010	pcrx	Change In Royalty Interest Obligation ChangeInRoyaltyInterestObligation	675000	USD
CY2009	pcrx	Change In Royalty Interest Obligation ChangeInRoyaltyInterestObligation	-185000	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-14000	USD
CY2010	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	98000	USD
CY2009	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	34000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	922000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-264000	USD
CY2009	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1130000	USD
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-360000	USD
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-124000	USD
CY2009	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-299000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	608000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-32000	USD
CY2009	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-244000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2549000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1118000	USD
CY2009	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	10625000	USD
CY2010	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1795000	USD
CY2009	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	215000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	87158000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	50705000	USD
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	21038000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	20035000	USD
CY2010	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	19056000	USD
CY2009	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-5309000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7077000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12386000	USD
CY2011	us-gaap	Interest Paid InterestPaid	4739000	USD
CY2010	us-gaap	Interest Paid InterestPaid	2371000	USD
CY2009	us-gaap	Interest Paid InterestPaid	1714000	USD
CY2011	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	907000	USD
CY2011	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	51222000	USD
CY2011	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4314000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4071000	USD
CY2009	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4146000	USD
CY2011	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	85000	USD
CY2010	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	-35000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2328000	USD
CY2009	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3793000	USD
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	27000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1782000	USD
CY2009	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3027000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24880000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20838000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6167000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6770000	USD
CY2009	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5509000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	7490000	USD
CY2009	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	524000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	537000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-22949000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1692000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	135000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2493000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37109000	USD
CY2011	pcrx	Stock Issued During Period Value Follow On Public Offering Issues StockIssuedDuringPeriodValueFollowOnPublicOfferingIssues	49006000	USD

Files In Submission

Name	View Source	Status
0001104659-12-021373-index-headers.html	Edgar Link	pending
0001104659-12-021373-index.html	Edgar Link	pending
0001104659-12-021373.txt	Edgar Link	pending
0001104659-12-021373-xbrl.zip	Edgar Link	pending
a12-2150_110k.htm	Edgar Link	pending
a12-2150_1ex21d1.htm	Edgar Link	pending
a12-2150_1ex23d1.htm	Edgar Link	pending
a12-2150_1ex31d1.htm	Edgar Link	pending
a12-2150_1ex31d2.htm	Edgar Link	pending
a12-2150_1ex32d1.htm	Edgar Link	pending
a12-2150_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g21501bci001.gif	Edgar Link	pending
pcrx-20111231.xml	Edgar Link	completed
pcrx-20111231.xsd	Edgar Link	pending
pcrx-20111231_cal.xml	Edgar Link	unprocessable
pcrx-20111231_def.xml	Edgar Link	unprocessable
pcrx-20111231_lab.xml	Edgar Link	unprocessable
pcrx-20111231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2011 Form 10-K Financial Statement

#000110465912021373 Filed on March 27, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2011 Form 10-K Financial Statement

#000110465912021373 Filed on March 27, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx